| Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. | |
MedLine Citation:
|
PMID: 20156671 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effect of the targeted cytotoxic somatostatin (SST) analog AN-162, consisting of doxorubicin (DOX) conjugated to SST carrier RC-121, was investigated on the growth of human colorectal cancer (CRC) cell lines HT-29, HCT-15, and HCT-116 and a DOX-resistant mouse leukemia cell line P388/R84. mRNA for SST-receptors and high affinity binding sites for SST were detected in all CRC cell lines and in P388/R84 cells. In contrast to DOX alone, AN-162 blocked HCT-116 cells and P388/R84 cells in S/G2 phase and increased the number of apoptotic cells. In vivo, AN-162 reduced the volume of CRC xenografts more effectively than its unconjugated components. Our results suggest that AN-162 inhibits growth of experimental CRC more effectively than DOX and increases sensitivity of DOX resistant human leukemia cells. |
Authors:
|
Florian Hohla; Stefan Buchholz; Andrew V Schally; Awtar Krishan; Ferenc G Rick; Luca Szalontay; Andrea Papadia; Gabor Halmos; Frank Koster; Elmar Aigner; Christian Datz; Stephan Seitz |
Publication Detail:
|
Type: Journal Article Date: 2010-02-13 |
Journal Detail:
|
Title: Cancer letters Volume: 294 ISSN: 1872-7980 ISO Abbreviation: Cancer Lett. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-05-24 Completed Date: 2010-07-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600053 Medline TA: Cancer Lett Country: Ireland |
Other Details:
|
Languages: eng Pagination: 35-42 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved. |
Affiliation:
|
Department of Internal Medicine, General Hospital Oberndorf, Teaching Hospital of the Paracelsus Private Medical University of Salzburg, Paracelsusstrasse 37, Oberndorf, Austria. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
2-Hydroxyphenethylamine
/
analogs & derivatives*,
therapeutic use Aniline Compounds / therapeutic use* Animals Cell Cycle / drug effects Cell Division Cell Survival / drug effects Colonic Neoplasms / genetics, pathology* Colorectal Neoplasms / epidemiology, mortality Doxorubicin / therapeutic use* Drug Resistance, Neoplasm* Female Humans Leukemia, Experimental / drug therapy Male Mice Mice, Nude RNA, Messenger / genetics Receptors, Somatostatin / genetics Reverse Transcriptase Polymerase Chain Reaction Somatostatin / analogs & derivatives*, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Aniline Compounds; 0/RNA, Messenger; 0/Receptors, Somatostatin; 0/somatostatin receptor 5; 0/somatostatin receptor subtype-4; 0/somatostatin receptor type 1; 23214-92-8/Doxorubicin; 33189-65-0/N-(2-diethylaminoethyl)-N-(2-hydroxy-2-phenylethyl)-2,5-dichloroaniline; 51110-01-1/Somatostatin; 7568-93-6/2-Hydroxyphenethylamine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Amino-functionalized single-chain bolalipids: Synthesis and aggregation behavior of new basic buildi...
Next Document: Surgical Management of Non-small Cell Lung Cancer with Mediastinal Lymphadenopathy.